TB Alliance Congratulates Dr. Kathleen Schostack on Her Retirement
As Senior Vice President of Program and Alliance Management, Dr. Schostack played a vital role in advancing TB drug development […]
News
Realizing our “Triple-A Mandate”
Four years ago, TB Alliance secured the first regulatory approval from the United States Food and Drug Administration (US FDA)
TB Alliance Issues Call for Researchers to Access TB Biomarker Repository
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with
Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.
TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines.
TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to
With One and a Half Million People Dying from TB Every Year, It’s Time to Accelerate Progress
The public health progress in the World Health Organization’s Global Tuberculosis (TB) Report 2019 this year can be found in
TB Alliance Statement on TB REACH Wave 7
TB Alliance applauds the Stop TB Partnership’s TB REACH program for investing in efforts to combat tuberculosis (TB). The $15.4
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S.
TB Community Urges Global Leaders to “Walk the Talk” on Investing in TB Research
On July 28th in South Africa, more than 100 members of the TB research community marched under the Louder than